Advertisement
Corrigendum
Open Access | 10.1172/JCI199353
Find articles by Liao, Q. in: PubMed | Google Scholar
Find articles by Zhou, X. in: PubMed | Google Scholar
Find articles by Wu, L. in: PubMed | Google Scholar
Find articles by Yang, Y. in: PubMed | Google Scholar
Find articles by Zhu, X. in: PubMed | Google Scholar
Find articles by Liao, H. in: PubMed | Google Scholar
Find articles by Zhang, Y. in: PubMed | Google Scholar
Find articles by Lian, W. in: PubMed | Google Scholar
Find articles by Zhang, F. in: PubMed | Google Scholar
Find articles by Wang, H. in: PubMed | Google Scholar
Find articles by Ding, Y. in: PubMed | Google Scholar
Find articles by
Zhao, L.
in:
PubMed
|
Google Scholar
|
Published October 1, 2025 - More info
Colorectal cancer (CRC) is characterized by an immune-suppressive microenvironment that contributes to tumor progression and immunotherapy resistance. The gut microbiome produces diverse metabolites that feature unique mechanisms of interaction with host targets, yet the role of many metabolites in CRC remains poorly understood. In this study, the microbial metabolite 4-hydroxybenzeneacetic acid (4-HPA) promoted the infiltration of PMN myeloid-derived suppressor cells (PMN-MDSCs) in the tumor microenvironment, consequently inhibiting the antitumor response of CD8+ T cells and promoting CRC progression in vivo. Mechanistically, 4-HPA activates the JAK2/STAT3 pathway, which upregulates CXCL3 transcription, thereby recruiting PMN-MDSCs to the CRC microenvironment. Selective knockdown of CXCL3 resensitized tumors to anti-PD-1 immunotherapy in vivo. Chlorogenic acid reduces the production of 4-HPA by microbiota, likewise abolishing 4-HPA–mediated immunosuppression. The 4-HPA content in CRC tissues was notably increased in patients with advanced CRC. Overall, the gut microbiome uses 4-HPA as a messenger to control chemokine-dependent accumulation of PMN-MDSC cells and regulate antitumor immunity in CRC. Our findings provide a scientific basis for establishing clinical intervention strategies to reverse the tumor immune microenvironment and improve the efficacy of immunotherapy by reducing the interaction among intestinal microbiota, tumor cells, and tumor immune cells.
Qing Liao, Ximing Zhou, Ling Wu, Yuyi Yang, Xiaohui Zhu, Hangyu Liao, Yujie Zhang, Weidong Lian, Feifei Zhang, Hui Wang, Yanqing Ding, Liang Zhao
Original citation: J Clin Invest. 2025;135(11):e181243. https://doi.org/10.1172/JCI181243
Citation for this corrigendum: J Clin Invest. 2025;135(19):e199353. https://doi.org/10.1172/JCI199353
The original article omitted the following information for accessing sequencing data:
The raw sequencing data were deposited in a public repository, the NCBI Sequence Read Archive (SRA) (https://www.ncbi.nlm.nih.gov/sra; Bioproject accession number PRJNA1302563). Group-level metadata are available from the corresponding author under execution of a streamlined Data Transfer Agreement (DTA) upon reasonable request and IRB approval.
The HTML and PDF files have been updated with this information.
The authors regret the error.